HOUSTON, TX / ACCESSWIRE / June 7, 2016 / First Titan Corp. (OTCQB: FTTN) (the “Company“) is proud to announce the acquisition of AngioSoma, Inc., effective ten (10) days after the filing of a Form 14F with the SEC. The acquisition of AngioSoma, Inc. as a subsidiary of the Company provides diversification outside of the depressed oil & gas industry and significant upside potential with the intellectual property licensed by AngioSoma, Inc.

On June 3, 2016, the Company entered into an Agreement and Plan of Reorganization (the “Agreement”) with AngioSoma Research, Inc., a Texas corporation, a newly formed wholly owned subsidiary of the Company, AngioSoma, Inc., a Nevada corporation, and the stockholders of AngioSoma, Inc. Pursuant to the Agreement, AngioSoma Research, Inc. will merge with and into AngioSoma, Inc., and the Company’s name will change to AngioSoma, Inc. The surviving corporation, AngioSoma Research, Inc., will be domiciled in Texas as a wholly owned subsidiary of the Company under its new name AngioSoma, Inc. The purchase price for the acquisition consists of the issuance by the Company of 20,000,000 shares of our Common Stock, par value $0.001 per share to the stockholders of AngioSoma, Inc.

Further information is available on Forms 8K and 14F filed with the US Security and Exchange Commission, available at http://www.sec.gov.

ABOUT FIRST TITAN CORP.

First Titan Corp. (http://www.firsttitanenergy.com), through its wholly owned subsidiary, First Titan Energy, LLC, is committed to the exploration and development of oil and natural gas resources around the globe. The Company continually seeks to partner with energy developers that are pursuing innovative new methods of oil and gas extraction, including the development of new technologies, cleaner methods and unconventional resources.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (http://www.angiosoma.com), a Texas corporation based in Montgomery, Texas, acquired the rights to Liprostin™, a Peripheral Artery Disease therapy using FDA approved Alprostadil™ packaged inside a proprietary Liposome for controlled drug release. Phase II Clinical Trials (a-b-c) had been completed with excellent results treating intermittent claudication (pain from walking) and non-healing ulceration. Data shows Liprostin™ is more than twice as effective as and four times faster than FDA approved drug Cilostazol™ for treating intermittent claudication. A huge, non-healing ulceration was eliminated in 200 days. We have established our protocols and are ready to retain a Contract Research Organization to conduct Clinical Trials Phase III with the 60 patient protocol approved by the FDA, which will take approximately 12 months to complete.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:

First Titan Corporation
Sydney Jim, 702-448-8148
President and CEO
info@firsttitanenergy.com

SOURCE: First Titan Corporation

ReleaseID: 440865

VANCOUVER, BC / ACCESSWIRE / June 7, 2016 / AMERICAN VANADIUM CORP. (TSXV: AVC) (OTC: AVCVF) (“American Vanadium” or the “Company”) announces that Robert B. Catell and Oleg Popovsky have informed the Company that they do not intend to stand for re-election as directors of the Company at the upcoming annual general and special meeting of the shareholders (the “Meeting”) scheduled for July 14, 2016.

Accordingly, the following individuals will be presented as the management nominees for directors at the Meeting:

William J. Radvak, Current Director
Brian E Bayley, Current Director
Brett Whalen, Current Director
Donn Burchill, New Nominee

“We would like to take this opportunity to sincerely thank Messrs. Catell and Popovsky for their dedication and contribution to the Company during their term as directors of the Company. It was a pleasure to have had the opportunity to work with people of Bob and Oleg’s caliber,” said Bill Radvak, President & CEO of American Vanadium.

About American Vanadium Corp.

American Vanadium is the Master Sales Agent in North America for GILDEMEISTER energy solution’s CellCube energy storage system. The CellCube is the world’s leading commercially available vanadium flow battery, providing long duration solutions over a 20+ year life for a broad range of applications including renewable energy integration and demand charge reduction. CellCube is a powerful, durable and reliable energy storage system that ensures a clean, emission-free energy supply at all times.

ON BEHALF OF THE BOARD

Bill Radvak, President and CEO

For further information, please contact:

Bill Radvak, President & CEO
(778) 888 4101
bradvak@americanvanadium.com
www.americanvanadium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY HEREIN.

SOURCE: American Vanadium Corp.

ReleaseID: 440866

WOODSTOCK, ON / ACCESSWIRE / June 7, 2016 / Tropic International Inc. (OTCQB: TRPO) (“Tropic”), a Nevada corporation in the business of developing and commercializing innovative technologies, is pleased to announce that it has entered into a share exchange agreement with Notox Bioscience Inc., a private Nevada corporation (“Notox”), and all the shareholders of Notox, pursuant to which Notox is expected to become a wholly owned subsidiary of Tropic.

Notox was recently formed for the purpose of acquiring 100% of the right, title and interest in and to an exclusive license agreement with The Cleveland Clinic Foundation (the “Clinic”) currently held by a private Ontario corporation. The license agreement grants the holder the exclusive license to certain patented intellectual property of the Clinic relating to the treatment of a neuromuscular defect developed by Dr. Frank Papay, MD, FACS Chairman Dermatology and Plastic Surgery Institute, Cleveland Clinic, making it the world’s first credible and healthier non-toxic alternative to Botox, and in particular, the ability to produce and sell products that incorporate such intellectual property in the fields of aesthetics and pain.

The share exchange agreement provides that the current shareholders of Notox will receive 100 million restricted shares of Tropic’s common stock at the closing in exchange for selling all of their Notox shares to Tropic, and contains a number of closing conditions, including the execution of an agreement that assigns the private Ontario corporation’s rights and obligations under the license agreement to Notox. The share exchange agreement also includes a covenant of Tropic that it will complete a 1:2 reverse split within 90 days of the closing date. Upon the completion of the transaction, of which there is no guarantee, the reverse split, the conversion of preferred shares of an existing Tropic subsidiary in June 2017, the exchange of certain other outstanding shares of another existing Tropic subsidiary and the issuance of certain shares pursuant to subscriptions received, Tropic will have approximately 108 million issued and outstanding shares of common stock.

John Marmora, Tropic’s President and CEO, stated: “The execution of the Notox share exchange agreement represents an extremely important milestone for Tropic. Over the past few years we have been working diligently to bring value to Tropic’s shareholders, and acquiring Notox and the rights to the Cleveland Clinic license agreement should allow us to achieve those goals. I look forward to building Notox into a globally recognizable brand and enabling Tropic to move forward as a successful enterprise for years to come.”

This news release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold in the United States except in compliance with one or more exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws.

About Tropic International Inc.

Tropic International Inc. (OTCBB: TRPO) (OTCQB: TRPO) is in the business of developing and commercializing an innovative home mist tanning system through its majority owned Ontario, Canada subsidiary, Tropic Spa Inc. The company’s goal is to market a unique, affordable system for convenient home use that delivers a full-body application and eliminates the harmful health effects associated with traditional tanning beds such as exposure to ultraviolet (UV) radiation, the consequences of which have been well-documented by numerous organizations including the American Cancer Society and the Canadian Cancer Society.

Tropic International Inc. has finalized the design of its home mist tanning system, applied for and acquired United States and Australian patents and has patents pending for Canada, China and the European Union.

For full product information, please visit the company’s website at www.tropicspatan.com.

Contact:

John Marmora – CEO
info@tropicspatan.com

Safe Harbor Statement and Forward-Looking Statements

This news release may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors which may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward looking statements. Forward-looking statements reflect the company’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. Such statements may include, but are not limited to, information related to: the company’s ability to complete the acquisition of Notox; anticipated operating results; relationships with customers; consumer demand; financial resources and condition; changes in revenues; changes in profitability; changes in accounting treatment; cost of sales; selling, general and administrative expenses; interest expense; the ability to produce the liquidity or enter into agreements to acquire the capital necessary to continue operations and take advantage of opportunities; legal proceedings and claims. Except as required by law, the company assumes no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

SOURCE: Tropic International Inc.

ReleaseID: 440863

LOS ANGELES, CA / ACCESSWIRE / June 7, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Intrexon Corporation (“Intrexon” or the “Company”) (NYSE: XON) concerning possible violations of federal securities laws between May 12, 2015 and April 20, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 6, 2016, lead plaintiff motion deadline.

For more information or to participate, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) Intrexon was overstating its revenue; and (2) as a result, Defendants’ statements about Intrexon’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com

SOURCE: Lundin Law PC

ReleaseID: 440861

BALA CYNWYD, PA / ACCESSWIRE / June 7, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Demandware, Inc. (“Demandware” or “the Company”) (NYSE: DWRE) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Salesforce.com, Inc, (“Salesforce”).

Click here to learn more about the investigation http://brodsky-smith.com/1086-dwre-demandware-inc.html, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Demandware shareholders will receive only $75.00 in cash for each share of Demandware stock they own. The investigation concerns whether the Board of Demandware breached their fiduciary duties to shareholders and whether Salesforce is underpaying for the Company. The transaction may undervalue the Company and would result in no real gain for many Demandware shareholders. Demandware is the premier SaaS e-commerce platform vendor. Consequently, it has been reported, that Salesforce is creating a new cloud called commerce cloud which has Demandware at its core. In addition, Demandware stock traded at $75.66 per share on July 31, 2015 and an analyst has set a price target for Demandware stock at $100.00 per share.

If you own shares of Demandware stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://brodsky-smith.com/1086-dwre-demandware-inc.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 440862

ZURICH, SWITZERLAND / ACCESSWIRE / June 7, 2016 / Today, an update on Equitas Resources Corp. (TSX.V: EQT) was published by Stephan Bogner from Rockstone Research as the company was halted trading yesterday at the open and disclosed earlier today to have signed a long-term funding agreement with CRH (Cartesian Royalty Holdings Pte. Ltd., an affiliate of Cartesian Capital Group, a global private equity fund managing in excess of $2.5 billion USD).

When you look around in today’s gold space, this $6 million USD deal is quite “innovative,” as CEO Chris Harris called it. However it is more than that, it’s quite generous and highly advantageous for Equitas. The company is now in the enviable position to have attracted a committed and strong financial partner for the long haul, which will not only result in advancing to production quicker than expected but also with less risks for shareholders.

With this long-term funding agreement in place, Equitas will also be ready, willing, and able for further acquisition opportunities in Brazil. Today’s deal provides strong protection against future shareholder dilution over the next 5 years, during which time the $6 million USD is expected to more than cover the projected development and acquisition expenditure for its Cajueiro Gold Mining Project in the Mato Grosso and Para states of Brazil.

The full research report can be accessed with the following links:

English (PDF):
http://rockstone-research.com/images/PDF/Equitas12en.pdf

English (web version):
http://rockstone-research.com/index.php/en/research-reports/1153-Equitas-secures-innovative-funding-for-an-unique-opportunity

German (PDF):
http://rockstone-research.com/images/PDF/Equitas12de.pdf

Disclaimer: Please read the full disclaimer within the full research
report as a PDF as fundamental risks and conflicts of interest exist.

SOURCE: Rockstone Research

ReleaseID: 440859

STUTTGART, GERMANY / ACCESSWIRE / June 7, 2016 / Medicus Homecare Inc. (OTC Pink: MDCRE) (the “Company“) is pleased to inform its shareholders that it has recently filed its Quarterly Report on Form 10-Q on June 3, 2016 for the quarter ended June 30, 2015. The financial statements of the Company for the three month period ended June 30, 2015 showed $2,346,320 ($3,707,154 for the six months) was generated from the medical in-home care services provided in Germany. After the costs of providing the services, the Company had net revenues of $521,184 ($743,514 for the six months) and net income of $165,787 ($280,828 for the six months).

Dr. Orhan Karahodza, the President and a Director of the Company, stated, “We are extremely pleased to finally have completed our quarterly report for the quarter ended June 30, 2015. We would like to thank our shareholders for their support during the transition to a public company.”

Mr. Nowek, CFO, says, “The Company is well on its way to completing the two remaining overdue quarterly reports for the quarters ended September 30, 2015 and March 31, 2016 and annual report of the year ended December 31, 2015. All information for those reports is currently being reviewed by the Company’s accountants and independent auditor (scheduled for June 2016) and the next first filing is targeted for June 2016.”

Mr. Nowek thinks that once these filings are finalized the Company has a unique opportunity for growth through natural expansion and acquisition.

ABOUT MEDICUS HOMECARE INC.

The Company offers medical in-home care services in Germany including ventilation for patients that suffer from debilitating diseases such as Amyotrophic Lateral Sclerosis (ALS), Muscular Dystrophy (MD), Guillain-Barre syndrome (GBS), and Chronic Obstructive Pulmonary Disease (COPD). Other services provided by the Company include acute post-patient care, respiration optimization and monitoring of long-term home respiration.

For additional information regarding the Company, please visit www.medicushomecareinc.com, or email info@medicus-24.de or telephone +49 157 894 69537.

On behalf of the Board,

Dr. Orhan Karahodza
President and Director

Notice Regarding Forward-Looking Statements

This news release may contain forward-looking statements (within the meaning of applicable securities laws) relating to business of the Company and the environment in which it operates. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. These statements are based on the Company’s expectations, estimates, forecasts and projections and include statements relating to trading of the warrants. They are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. These risks and uncertainties are discussed in the Company’s regulatory filings available on EDGAR or in the Company’s Form 10-KT for the fiscal year ended December 31, 2014, filed on December 28, 2015, and in the Company’s Form 10-Q for the quarter ended June 30, 2015. There can be no assurance that forward-looking statements will prove to be accurate as actual outcomes and results may differ materially from those expressed in these forward-looking statements. Readers, therefore, should not place undue reliance on any such forward-looking statements. Further, a forward-looking statement speaks only as of the date on which such statement is made. The Company undertakes no obligation to publicly update any such statement or to reflect new information or the occurrence of future events or circumstances.

SOURCE: Medicus Homecare Inc.

ReleaseID: 440858

CORAL GABLES, FL / ACCESSWIRE / June 7, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. Helios and Matheson Analytics Inc. (HMNY), LifeClips Inc. (LCLP), China Auto Logistic Inc. (CALI) and Aehr Test Systems (AEHR) have been added to our watch list today. Continue reading to find out why. – To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.

Helios and Matheson Analytics Inc. (NASDAQ: HMNY) has seen a large increase in trading volume and stock price this week. On Monday the stock traded more than 9 million shares and over the course of the last two days, the stock has seen highs of $10. The move seems to have sparked from the company’s announcement that they plan to merge. In discussing the pending merger, Ted Farnsworth, Founder and CEO of RedZone Maps, said, “Upon discovering Helios and Matheson’s cutting edge capabilities in Big Data analytics and artificial intelligence, we saw the synergy immediately. I believe the combined company will be able to offer the most sophisticated and advanced technology in global crime mapping. Our mission is to enhance personal safety worldwide.” You Can View HMNY’s News Here.

Stay Informed and Up To Date On The Hottest Small Cap NASDAQ & OTC Plays. Get Them Here.

LifeClips Inc. (OTC: LCLP) announced this week that the company had confirmed the signing of Huey Long & Associates as a retail representative for Life Clips. Mr. Long brings with him tremendous sourcing abilities, logistics expertise, marketing and sales distribution opportunities, all of which will be deployed toward Life Clips, Inc. (LCLP). Some of the channels that Mr. Long works with include, Wal-Mart, Sam’s Club, AT&T, Costco, Amazon, Target, Ebags and numerous other retail stores. Since the beginning of the week, LCLP has seen an increase in trading volume followed by stronger price movement on Tuesday. The stock has managed to climb 12% after hitting lows on Monday of $0.57 and is currently trading near Tuesday’s highs of the day at $0.64. Get More Information on LCLP Now!

Enjoy picks like this? Get These Alerts and More on top small cap Companies before They Rally, Text the phrase “StockAlerts” to 82257.

China Auto Logistic Inc. (NASDAQ: CALI) has has realized a significant increase in price and volume on Tuesday. The company announced today that effective June 1, 2016, 100% of the equity in its Zhonghe subsidiary — the owner and operator of the Airport International Auto Mall in Tianjin and 40% owner of Tianjin Car King — has been sold to Wuxi Huitong Automobile Sales and Service Co., Ltd. (Huitong) for approximately $62.3 million. Following this announcement, shares of CALI increased to highs of $4.399 equating to a jump of more than 300% from Monday’s closing price of $1.05. You can view the full CALI press release HERE.

Stay Informed and Up To Date On The Hottest Small Cap Stocks; Free To Join Now

Aehr Test Systems (NASDAQ: AEHR) announced this morning that it has received the first order for its new FOX-XP production test cell. The order totals over $4.5 million. Specifics of the deal include $1.4 million of the order is shippable and payable immediately, and the remaining shipments and revenue from this sale are expected to continue through early calendar 2017. Since opening the day at $1.25, shares of AEHR have increased to highs of $3.4199 and marked a jump of 174%. Get more information on AEHR now, Click Here.

Small Cap Stock Alerts: Get Them straight to your Cell Phone. To Receive Our Winning Small Cap Stock Alerts For Free, text “StockAlerts” to 82257.

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. You can subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase “StockAlerts” to 82257.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. A full disclaimer can be found at www.DailyStockReporter.com/disclaimer.

EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

EGM FIRM INC, which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.

EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

CONTACT:

Company: DailyStockReporter.com
Contact Email: news@dailystockreporter.com

SOURCE: DailyStockReporter.com

ReleaseID: 440857

NEW YORK, NY / ACCESSWIRE / June 7, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased LDR Holding Corporation (NASDAQ: LDRH) stock prior to June 7, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of LDR Holding Corporation to Zimmer Biomet Holdings, Inc. (NYSE: ZBH) for $37.00 in cash for each LDR Holding share. To learn more about the action and your rights, go to: http://zlk.9nl.com/ldr-holding-ldrh or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440856